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Somatic hypermutation (SHM) and class-switch 
recombination (CSR) represent physiological 
processes that modify variable (V) and constant 
regions of Ig genes in mature germinal center 
B cells (1). Both SHM and CSR critically 
depend on expression of activation-induced 
cytidine deaminase (AID), which introduces 
single-strand breaks into target DNA (2). AID-
mediated DNA single-strand breaks (DNA-
SSB) leading to SHM and CSR are specifi  cally 
introduced into V or constant regions of Ig 
genes, respectively. At much lower frequency, 
however, AID can also target non-Ig genes 
in germinal center B cells (3, 4) and may even 
act as a genome-wide mutator (5). Such target-
ing errors carry the risk of oncogenic muta-
tion leading to the transformation of a germinal 
center B cell, which may give rise to B cell 
lymphoma. For instance, aberrant SHM or CSR 
may lead to chromosomal translocation of pro-
tooncogenes, including MYC, BCL2, BCL6, and 
CCND1, and cause various types of B cell lym-
phoma (3). Therefore, tight regulation of AID 
expression in germinal center B cells and con-
trol of DNA strand breaks related to SHM and 
CSR are critical to prevent B cell malignancy. In 
fact, previous work demonstrated that Myc-Igh 
chromosome translocations as they occur in hu-
man Burkitt’s lymphoma are caused by Aid (6). 
The emergence of Myc-Igh gene rearrangements 
is not only prevented by tight regulation of Aid 
expression; the activation of DNA damage–
induced checkpoints during physiological AID-
dependent CSR may eventually lead to the 
activation of the tumor suppressors ATM, NBS1, 
CDKN2D (INK4D, P19/ARF), and TP53 and 
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The Philadelphia chromosome (Ph) encoding the oncogenic BCR-ABL1 kinase defi  nes a 
subset of acute lymphoblastic leukemia (ALL) with a particularly unfavorable prognosis. 
ALL cells are derived from B cell precursors in most cases and typically carry rearranged 
immunoglobulin heavy chain (IGH) variable (V) region genes devoid of somatic mutations. 
Somatic hypermutation is restricted to mature germinal center B cells and depends on 
activation-induced cytidine deaminase (AID). Studying AID expression in 108 cases of ALL, 
we detected AID mRNA in 24 of 28 Ph+ ALLs as compared with 6 of 80 Ph− ALLs. Forced 
expression of BCR-ABL1 in Ph− ALL cells and inhibition of the BCR-ABL1 kinase showed 
that aberrant expression of AID depends on BCR-ABL1 kinase activity. Consistent with 
aberrant AID expression in Ph+ ALL, IGH V region genes and BCL6 were mutated in many 
Ph+ but unmutated in most Ph− cases. In addition, AID introduced DNA single-strand 
breaks within the tumor suppressor gene CDKN2B in Ph+ ALL cells, which was sensitive to 
BCR-ABL1 kinase inhibition and silencing of AID expression by RNA interference. These 
fi  ndings identify AID as a BCR-ABL1–induced mutator in Ph+ ALL cells, which may be 
relevant with respect to the particularly unfavorable prognosis of this leukemia subset.
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is indeed critical to prevent oncogenic Myc-Igh gene rear-
rangements (7).
RESULTS
Aberrant AID expression correlates with the Philadelphia 
chromosome (Ph) in acute lymphoblastic leukemia (ALL)
ALL cells are typically derived from pro– or pre–B cells. 
These B cell precursors do not express AID (Table I and 
Fig. 1 A, left) and carry Ig genes that have neither under-
gone SHM nor CSR (8). Therefore, it was unexpected that 
AID is expressed in a subset of ALL cell lines (Table I and 
Fig. 1 A, right). Interestingly, AID expression correlates with 
the presence of t(9;22)(q34;q11), resulting in the so-called 
Philadelphia chromosome (Ph). Ph encodes the oncogenic 
BCR-ABL1 kinase and defi  nes a subgroup of ALL with a 
particularly unfavorable prognosis (9). Studying AID mRNA 
expression in 108 cases of ALL, AID mRNA was detected 
in 24 of 28 cases of Ph+ ALL, but only in 6 of 80 cases of 
Ph− ALL (Table I). Compared with normal germinal center 
B cells, mRNA levels for AID are lower in most but similar 
in some Ph+ ALL cell lines (Fig. 1 A, right).
SHM and CSR of Ig genes in Ph+ ALL
This raises the possibility that Ig V region genes might ab-
errantly be targeted by SHM in Ph+ ALL. Therefore, we 
analyzed the sequence of VH region genes in 60 Ph− and 
46 Ph+ cases of ALL. Among Ph− ALL, 6 of 60 cases carry 
somatically mutated VH region genes (Table I and Table S1, 
which is available at http://www.jem.org/cgi/content/full/
jem.20062662/DC1). In contrast, 30 of 46 Ph+ ALL cases 
harbor mutated VH gene rearrangements (Table I and Table S2). 
Counting only Ph+ and Ph− leukemia cases, for which in-
formation on both AID expression and VH region sequence 
was available, this correlation was even more conspicuous: 
16 of 18 Ph+ leukemia cases, all expressing AID, also carried 
mutated VH region genes, whereas 10 Ph− leukemia cases, all 
lacking AID expression, also all carried unmutated VH gene 
rearrangements. The average mutation frequency was 34.5 ± 4 
mutations/103 bp in Ph+ and 4.9 ± 1 mutations/103 bp in 
Ph− ALL among all sequences (means based on data from 70 
and 76 sequences ± SEM, P < 0.05; Tables S1 and S2). Also 
among the six Ph− cases carrying mutated VH region genes, 
the mutation frequency was high, suggesting that in a small 
subset of Ph− ALL, aberrant SHM may also be induced by 
other factors that are not related to BCR-ABL1.
Analyzing CSR of Ig CH region genes in Ph+ and Ph− 
ALL, we identifi  ed switched Cγ1, Cγ2, Cγ3, and Cα2 tran-
scripts in 4 of 21 Ph+ but not in any of 10 Ph− ALL cases 
(Table II). Based on the small number of cases studied, we 
cannot give an estimate of the overall frequency of CSR in 
Ph+ ALL. Collectively, we conclude that Ig genes in Ph+ 
ALLs can be targeted by SHM and in rare cases even undergo 
CSR, which is consistent with specifi  c expression of AID in 
this ALL subset.
Aberrant SHM of non-Ig genes in Ph+ ALL
Given that previous studies demonstrated that aberrant SHM 
also involves mutation of non-Ig genes (3, 4), we also studied 
known potential target regions of SHM within the BCL6 and 
MYC genes (3, 4) in Ph− and Ph+ cases. 7 of 10 Ph+ ALL cases 
and 1 of 5 Ph− ALL cases harbored a mutated BCL6 gene 
(Table I and Table S3). In both Ph− and Ph+ ALL, the average 
mutation frequency was above the error rate of the PFU DNA 
polymerase used in this experiment. Comparing Ph+ and Ph− 
Table I.  Aberrant SHM of Ig- and non-Ig genes in Ph+ ALL cells
Cell type IGHVa BCL6 MYC
AID mRNA 
expression
Mutated clones/
cases
Mutations per 
103 bp
Mutated clones/
cases
Mutations per 
103 bp
Mutated clones/
cases
Mutations per 
103 bp
Pre–B cells (clones) 1/36 4.4 ± 4 n.d. n.d. No
Naive B cells (clones) 0/12 3.1 ± 1 1/21b 0.05b 7/179c 0.05c No
Germinal center B cells 
(clones) 12/14 40.2 ± 12 5/15b 1.0b n.d. Yes
Memory B cells (clones) 52/54 45.2 ± 9 26/71c 1.38 ± 0.34c 9/178c 0.09c No
Ph− ALL (cases) 6/60 4.85 ± 1.23 1/5d 0.11 ± 0.11 1/5c 0.16 ± 0.11 6/80 cases
Ph+ ALL (cases) 30/46 34.48 ± 4.42 7/10d 1.07 ± 0.23 3/9d 0.51 ± 0.15 24/28 cases
MYC-IGH 
Burkitt’s lymphoma 
(cases)
12/12b 69b 11/30b 0.4b 12/12b 1.9b Yes
aFor normal B cell subsets, rearranged VH gene segments were amplifi  ed, cloned, and sequenced from bulk populations. For leukemia and lymphoma cells, individual cases 
were analyzed. Mutation frequencies are given as means (mutations per 103 bp) ± standard error of the mean. VH gene rearrangements were amplifi  ed using Taq DNA 
polymerase. VH gene rearrangements amplifi  ed from ALL cases were considered mutated if the average mutation frequency of all amplifi  ed sequences was signifi  cantly 
(P < 0.01) above the error rate of Taq DNA polymerase.
bData from reference 3.
cData from reference 4.
dBCL6 and MYC alleles were amplifi  ed using PFU DNA polymerase and sequenced from both DNA strands. BCL6 or MYC alleles amplifi  ed from ALL cases were considered 
mutated if at least two mutated sequences were amplifi  ed per case with an average mutation frequency of all amplifi  ed sequences signifi  cantly (P < 0.01) above the error 
rate of PFU DNA polymerase. Only mutations confi  rmed on both DNA strands were counted.JEM VOL. 204, May 14, 2007  1159
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cases, the average mutation frequency was signifi  cantly higher 
in Ph+ ALL (Table I and Table S3; P < 0.05). Likewise, MYC 
gene mutations were found in both Ph− and Ph+ ALL cells. In 
this case, however, the diff  erence between Ph+ and Ph− cells 
was not signifi  cant (Table I; P = 0.13).
Besides rearranged IGH V region genes, CD19+ B cell 
lineage ALL cells frequently carry TCRB (10) and TCRG (11) 
gene rearrangements. Consistent with these previous fi  ndings, 
we were able to amplify TCRB and TCRG gene rearrange-
ments from four of eight (TCRB) and seven of seven (TCRG) 
cases of Ph+ ALL (Table S3, available at http://www.jem
.org/cgi/content/full/jem.20062662/DC1). Given that trans-
genic expression of Aid in murine T cell lymphomas also in-
duces SHM of rearranged TCRB genes (12), we performed 
sequence analysis of TCRB and TCRG gene rearrange-
ments in Ph+ ALL, as well as normal peripheral blood T cells 
(Table S3). TCRB gene rearrangements amplifi  ed from Ph+ 
ALL were somatically mutated in all four cases with an average 
Figure 1.  AID expression in Ph+ ALL cells. mRNA expression of AID 
was measured in normal human pro–B, pre–B, B1, naive, germinal center, 
and memory B cells as well as plasma cells by RT-PCR (A). In a semiquanti-
tative RT-PCR analysis, AID mRNA expression in Ph+ ALL cells was com-
pared with germinal center B cells and Ph− ALL cells. GAPDH was used for 
normalization of cDNA amounts (A). Ph+ ALL cell lines (BV173 and Nalm1; 
10 μmol/l STI571) and v-abl–transformed mouse pre–B cells (300-19; 
1 μmol/l STI571) were treated with or without STI571 for 24 h and subjected 
to semiquantitative RT-PCR analysis for human AID and GAPDH or murine 
Aid and Hprt mRNA expression (B). Protein lysates from STI571-treated or 
untreated Ph+ ALL cells (BV173) were used for Western blotting (C) to-
gether with antibodies against AID and EIF4E (used as a loading control). 
IL-3–dependent murine pro–B cells carrying a doxycycline-inducible BCR-
ABL1 transgene were incubated with or without 1 μg/ ml doxycycline for 
24 h and subjected to RT-PCR analysis of Aid, Oct2, and Obf1 mRNA ex-
pression (C). Ph− ALL cells were transiently transfected with a pMIG vector 
encoding GFP and/or GFP and BCR-ABL1. After 24 h, GFP-expressing cells 
were sorted and subjected to RT-PCR analysis for AID expression (C).1160  ABERRANT SOMATIC HYPERMUTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA | Feldhahn et al.
mutation frequency of 6.2 mutations per 103 bp (±2.3 muta-
tions per 103 bp, SEM), which was substantially above the 
mutation frequency of rearranged TCRB alleles amplifi  ed 
from normal T cells. Only 2 of 30 TCRB gene rearrangements 
amplifi  ed from normal T cells harbored a single mutation with 
an average mutation frequency of 0.2 ± 0.1 mutations per 
103 bp (P < 0.01; Table S3). Likewise, fi  ve of seven TCRG 
gene rearrangements amplifi  ed from Ph+ ALL cases carried 
somatic mutations with an average mutation frequency of 
5.7 ± 1.0 mutations per 103 bp. In contrast, only 1 in 16 TCRG 
gene rearrangements amplifi  ed from normal T cells harbored a 
single point mutation (average mutation frequency: 0.2 ± 0.2 
mutations per 103 bp, P < 0.01; Table S3). Collectively, these 
data indicate that besides rearranged Ig genes, non-Ig genes, 
namely BCL6, TCRB, and TCRG, can also be targeted by 
aberrant SHM in Ph+ ALL, which is consistent with aberrant 
expression of AID in this leukemia subset.
BCR-ABL1–induced AID expression in Ph+ ALL
We next investigated whether the Ph-encoded BCR-ABL1 
kinase contributes to aberrant AID expression in Ph+ ALL. 
As shown in Fig. 1, inhibition of BCR-ABL1 kinase activity 
by STI571 down-regulates AID expression in Ph+ ALL at 
the mRNA (Fig. 1 B) and protein levels (Fig. 1 C, left). Acti-
vation of transgenic expression of BCR-ABL1 in a murine 
pro–B cell line and forced transient expression of BCR-ABL1 
in a Ph− ALL (Fig. 1 C, middle and right) induce de novo 
expression of AID in these cells. To validate the causative 
link between BCR-ABL1 kinase activity and aberrant AID 
expression also in patients suff  ering from Ph+ ALL, we com-
pared four matched sample pairs of Ph+ ALL before the onset 
and during continued therapy with the BCR-ABL1 kinase 
inhibitor STI571 (Fig. 2). Confi  rming in vitro observations, 
primary patient–derived Ph+ ALL cells down-regulate AID 
mRNA (Fig. 2 A) and protein (Fig. 2 B) levels under ex-
tended treatment with the BCR-ABL1 kinase inhibitor STI571. 
We conclude that BCR-ABL1 kinase activity is essential for 
aberrant AID expression in Ph+ ALL cells.
Given that STI571 inhibits both oncogenic BCR-ABL1 
as well as physiologic ABL1 kinase activity, we investigated 
whether ABL1 kinase activity contributes to AID expression 
in normal germinal center–derived B cells. To this end, we 
isolated splenic B cells from C57/BL6 mice and cultured 
them in the presence or absence of 10 μmol/l STI571 in the 
presence or absence of 1 ng/ml IL-4 and 25 μg/ml LPS, or 
both IL-4/LPS and STI571 (Fig. S1, available at http://www
.jem.org/cgi/content/full/jem.20062662/DC1). To compare 
the eff  ect of ABL1 kinase inhibition in normal B cells and 
BCR-ABL1–transformed B cells, splenocytes from BCR-
ABL1–transgenic C57/BL6 litter mates were also cultured in 
the presence or absence of 10 μmol/l STI571. After 3 d, Aid 
mRNA levels were measured by real-time PCR as a ratio of 
Aid and Hprt mRNA levels. As described previously (13), 
activation of splenic B cells resulted in a dramatic increase of 
Aid mRNA expression. Aid mRNA levels in BCR-ABL1–
transgenic B cells were also constitutively higher than in 
B cells isolated from wild-type littermates (Fig. S1). Interestingly, 
ABL1 kinase inhibition through STI571 not only diminished 
Aid mRNA levels in BCR-ABL1–transgenic B cells, but also 
eff  ectively prevented the up-regulation of Aid in normal B 
cells upon stimulation by IL-4 and LPS. These fi  ndings are 
paralleled by the blastoid morphology and the formation of 
large cell aggregates of the Aid-expressing B cells. In the pres-
ence of STI571, however, IL-4 and LPS failed to induce a 
blastoid morphology and formation of cell aggregates (Fig. S1). 
Although we cannot exclude that the high concentrations 
of STI571 used in this experiment may inhibit other signaling 
molecules besides normal ABL1 in the splenic B cells, these 
Table II.  CSR in Ph+ ALL cells
Case VH DH JH rearrangement                                    CH region
LBCII (FACS-sort: 
CD19+ CD34+) 
Case 22 in Table S2
T  A  T  G  T  A  T  T  A  T  T  G  T  A  C  G  A  A  A  G  A 
T  A  T  G  T  A  T  T  A  T  T  G  T  A  C  G  A  A  A  G  A 
–G–––––––C–––G–––––––
VH3-30
G  G  G  T  T  C  A  G  C  T  A  T  G  G 
G  G  G  T  T  C  A  G  C  T  A  T  G  G 
––A–A–––––––––
DH5-5
C  C  G  A  C  C  T  G  A  A  C  T  T  C  T  G  G  G  G  C  C  A  G  G  G  A  A  C  C  C  T  G  G  T  C  A  C  C  G  T  C  T  C  C  T  C  A  G  G  G  A  G  T  G  C  A  T  C  C  G  C  C  C  C  A  A   Cμ
C  C  G  A  C  C  T  G  A  A  C  T  T  C  T  G  G  G  G  C  C  A  G  G  G  A  A  C  C  C  T  G  G  T  C  A  C  C  G  T  C  T  C  C  T  C  A  G  C  C  T  C  C  A  C  C  A  A  G  G  G  C  C  C  A  T   Cγ2
A–T––T–TG–––A–––––––––––––––––––––––––––––––––––––––––––––––––––––
JH4
LBCIII (FACS-sort: 
CD19+ CD34+)
Case 23 in Table S2
G  C  C  T  T  C  T  A  T  T  A  T  T  G  T  G  C  G  C  G  A 
G  C  C  T  T  C  T  A  T  T  A  T  T  G  T  G  C  G  C  G  A 
–––G–G–––––C––––––A––
VH1-46
GGTGATACC A  C  A  G  T  C  A  G  C  G  G  G  A 
GGTGATACC A  C  A  G  T  C  A  G  C  G  G  G  A 
––––––TG–
DH2-21
C  C  A  A  C  T  G  G  C  T  C  G  C  C  C  C  C  T  G  G  G  G  C  C  A  G  G  G  A  A  C  C  C  T  G  G  T  C  A  C  C  G  T  C  T  C  C  T  C  T  G  G  G  A  G  T  G  C  A  T  C  C  G  C  C  C  C  A  A   Cμ
C  C  A  A  C  T  G  G  C  T  C  G  C  C  C  C  C  T  G  G  G  G  C  C  A  G  G  G  A  A  C  C  C  T  G  G  T  C  A  C  C  G  T  C  T  C  C  T  C  T  G  C  C  T  C  C  A  C  C  A  A  G  G  G  C  C  C  A  T   Cγ2
A–––––––T–––A––––––––––––––––––––––––––––––––––––A–––––––––––––––––––
JH5
Ph+ cell line Nalm-1 A  G  T  C  T  G  A  G  A  G  C  T  G  A  G  G  A  C  A  C  C   TGGGGG
A  G  T  C  T  G  A  G  A  G  C  T  G  A  G  G  A  C  A  C  C   TGGGGG
A  G  T  C  T  G  A  G  A  G  C  T  G  A  G  G  A  C  A  C  C   TGGGGG
–––––––––A–––––––––––
VH3-43
T  A  C  T  T  T  G  A  C  T   ACTGGGGCC
T  A  C  T  T  T  G  A  C  T   ACTGGGGCC
T  A  C  T  T  T  G  A  C  T   ACTGGGGCC
––T–––––––
DH3-9
A  G  G  G  A  A  C  C  C  T  G  G  T  C  A  C  C  G  T  C  T  C  C  T  C  A  G  G  G  A  G  T  G  C  A  T  C  C  G  C  C  C  C  A  A   Cμ
A  G  G  G  A  A  C  C  C  T  G  G  T  C  A  C  C  G  T  C  T  C  C  T  C  A  G  C  T  T  C  C  A  C  C  A  A  G  G  G  C  C  C  A  T   Cγ3
A  G  G  G  A  A  C  C  C  T  G  G  T  C  A  C  C  G  T  C  T  C  C  T  C  A  G  C  A  T  C  C  C  C  G  A  C  C  A  G  C  C  C  C  A   Cα2
––––––––––––––––––––––––––––––––––––––––––––– 
JH5
Ph+ cell line SD1 G  C  T  G  T  C  T  A  T  T  A  T  T  G  T  G  T  G  A  A  A 
G  C  T  G  T  C  T  A  T  T  A  T  T  G  T  G  T  G  A  A  A 
–––––G–––––C––––C––––
VH3-30
C  C  G  A  T  G  G  G  A  C   C  C  T  A  C  C  G  C  G  A  G 
C  C  G  A  T  G  G  G  A  C   C  C  T  A  C  C  G  C  G  A  G 
–A–C–––T––
DH3-9
G  C  T  T  T  T  G  A  T  A  T  C  T  G  G  G  G  C  C  A  A  G  G  G  A  C  A  G  T  G  G  T  C  A  C  C  G  T  C  T  C  T  T  C  A  G  G  G  A  G  T  G  C  A  T  C  C  G  C  C  C  C  A  A   Cμ
G  C  T  T  T  T  G  A  T  A  T  C  T  G  G  G  G  C  C  A  A  G  G  G  A  C  A  G  T  G  G  T  C  A  C  C  G  T  C  T  C  T  T  C  A  G  C  C  T  C  C  A  C  C  A  A  G  G  G  C  C  C  A  T   Cγ1
–––––––––––––––––––––––––––A––––––––––––––––––––––––––––––––––– 
JH3
Sequence alignments of the VH and CH region genes of four Ph+ ALL cases (top) are compared to germline sequences (bottom). Constant regions are underscored. CSR was analyzed in 31 cases of ALL, 
including 10 cases of Ph− ALL (0/10 Ph− cases with CSR, all with Cμ) and 21 cases of Ph+ ALL (4/21 Ph+ cases with CSR: 1 Cγ1, 2 Cγ2, 1 Cγ3, 1 Cα2, in all 21 Ph+ cases also co-amplifi  cation of Cμ).JEM VOL. 204, May 14, 2007  1161
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fi  ndings suggest that Aid induction in normal B cells also re-
quires ABL1 kinase activity. Further experiments that address 
this possibility are currently under way. Of note, the same 
concentration of STI571 had no signifi  cant  eff   ect on Aid 
mRNA levels in a number of B cell lymphoma cell lines that 
exhibit constitutive expression of Aid (Fig. S2).
Our fi  nding that BCR-ABL1 induces aberrant AID ex-
pression in Ph+ ALL cells is in agreement with a recent study 
demonstrating that murine B cell precursors infected with the 
Abelson murine leukemia virus (Abelson-MuLV) also exhibit 
aberrant expression of Aid (14). The authors of this study 
  attribute aberrant Aid expression induced by the Abelson-
MuLV to retroviral infection and interpret aberrant Aid ex-
pression as an innate defense mechanism against the transforming 
retrovirus. Because both BCR-ABL1 and the transforming on-
cogene of the Abelson-MuLV, v-abl, share ABL1 kinase activ-
ity, the results we present here suggest that v-abl kinase activity 
may also contribute to aberrant expression of Aid in the 
murine B cell precursors infected by Abelson-MuLV. To test 
this hypothesis, we analyzed Aid expression in an Abelson-
MuLV–transformed murine pre–B cell line (300-19) in the 
presence or absence of STI571, which inhibits both BCR-
ABL1 and v-abl kinase activity (Fig. 1 B). In fi  ve repeat experi-
ments, inhibition of v-abl kinase activity resulted in substantial 
down-regulation of Aid expression in the Abelson-MuLV–
transformed 300-19 cells (Fig. 1 B). We conclude that v-abl 
kinase activity also contributes to Aid expression in Abelson-
MuLV–transformed pre–B cells. However, inhibition of v-abl 
did not abolish Aid expression entirely, which indicates that 
other factors leading to the up-regulation of Aid (e.g., the anti-
retroviral host defense proposed; reference 16) may indeed 
contribute to Aid expression in these cells as well.
BCR-ABL1–induced up-regulation of AID involves repression 
of ID2, a negative regulator of AID
Previous studies demonstrated that AID expression is tightly 
regulated by the transcription factor pair PAX5 and E2A and 
the E2A inhibitor ID2 (15, 16). Interestingly, previous work 
showed that ID2 is among the genes that are transcriptionally 
activated by STI571-induced ABL kinase inhibition in mu-
rine Abelson-MuLV–transformed pre–B cells (17). We there-
fore investigated the relationship between BCR-ABL1 kinase 
activity, E2A/PAX5, and their inhibitor ID2 with respect to 
regulation of AID expression in Ph+ ALL. Analyzing Aff  yme-
trix U133A 2.0 microarray data on two Ph+ ALL cell lines 
(BV173 and SUP-B15; the full dataset is available through 
GEO accession no. GSE7182) that were cultured in the pres-
ence or absence of 10 μmol/l STI571 for 16 h, we confi  rmed 
that inhibition of BCR-ABL1 kinase activity by STI571 in-
creased ID2 mRNA levels, whereas mRNA levels for PAX5 
and E2A did not change signifi  cantly (Fig. 3 A). In addition, 
the two Ph+ ALL cell lines were treated with STI571 for 48 h, 
and AID and ID2 protein levels were measured in the sur-
viving cells (annexin V−, propidium iodide−) by fl  ow cytom-
etry (Fig. 3 B). Although BCR-ABL1 kinase inhibition by 
STI571 decreased AID protein expression, levels of ID2 were 
clearly increased in the two Ph+ ALL cell lines (Fig. 3 B).
To test whether up-regulation of ID2 (as observed upon 
BCR-ABL1 kinase inhibition by STI571) leads to transcrip-
tional repression of AID in Ph+ ALL cells, we transduced two 
AID-expressing Ph+ ALL cell lines with a lentiviral vector 
encoding ID2 and GFP or GFP alone as a control. GFP+ cells 
were sorted and analyzed for mRNA levels of ID2 and AID 
using GAPDH as a reference gene (Fig. 3 C). Lentiviral over-
expression of ID2 indeed resulted in transcriptional inactiva-
tion of AID in both Ph+ ALL cell lines. These fi  ndings indicate 
that up-regulation of AID by BCR-ABL1 involves transcrip-
tional repression of ID2, which would act as a negative regula-
tor of AID in the absence of BCR-ABL1 kinase activity.
AID-induced DNA-SSB in Ph+ leukemia cells
Consistent with an active SHM mechanism, we detected   
footprints of ongoing subclonal diversifi  cation of VH gene 
segments in 11 of 46 cases of Ph+ ALL (Table S2). Refl  ecting 
their clonal evolution, several early mutations are common 
Figure 2.  AID expression in patient-derived Ph+ ALL cells de-
pends on BCR-ABL1 kinase activity in vivo. Matched sample pairs 
from four patients with Ph+ ALL before the onset and during continued 
treatment with the BCR-ABL1 kinase inhibitor STI571 were analyzed for 
AID mRNA levels by semiquantitative RT-PCR (A). The content of Ph+ 
ALL cells in all samples was normalized by BCR-ABL1 fusion transcripts 
(A), with “p190” and p210” indicating the two different breakpoints. 
Protein lysates from the same Ph+ ALL cases were also subjected to 
Western blot analysis for AID expression using EIF4E as a loading 
control (B). Protein lysates from CD19+ tonsillar B cells were used as 
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among many subclones, which diff  er from each other by sub-
sequently introduced diversifying mutations. As an example, 
genealogic trees for four VH gene rearrangements amplifi  ed 
from Ph+ ALL cell lines are shown in Fig. 4. To test whether 
AID expression and aberrant SHM are indeed causally linked 
in Ph+ ALL, we studied DNA-SSB within rearranged Ig VH 
genes and the tumor suppressor gene CDKN2B in the pres-
ence and absence of AID.
CDKN2B encodes the p15/INK4B tumor suppressor, 
which is frequently deleted in Ph+ ALL and lymphoid blast 
crisis (LBC) of Ph+ chronic myeloid leukemia (18, 19). 
Therefore, we silenced AID expression in three Ph+ ALL cell 
lines by RNA interference (Fig. 5 A) and studied the eff  ect 
of AID knockdown on DNA-SSB in rearranged VH genes 
and the CDKN2B locus. AID targeting and nontargeting 
small interfering RNA (siRNA) duplexes were fl  uorochrome 
labeled and repeatedly transfected into Ph+ ALL cells by nu-
cleofection. At a transfection effi   ciency between 3 and 10%, 
fl  uorochrome-labeled cells were sorted by fl  ow cytometry 
and subjected to further analysis. RNA interference substan-
tially reduced AID mRNA levels in all three Ph+ ALL cell 
lines (Fig. 5 A). Comparing Ph+ ALL cells carrying non-
targeting siRNAs with Ph+ ALL cells carrying AID-specifi  c 
siRNA duplexes, DNA-SSB were detected within re-
arranged VH gene segments as well as within the CDKN2B 
gene in the former but not in the latter case (Fig. 5 B). Like-
wise, inhibition of BCR-ABL1 kinase activity by STI571, 
leading to down-regulation of AID (Fig. 1), largely reduced 
the frequency of DNA-SSB within VH and CDKN2B genes 
(Fig. 5 B). We conclude that DNA-SSB introduced into 
both rearranged VH region genes and the  tumor suppressor 
gene CDKN2B require AID expression. To search for actual 
somatic mutations within the CDKN2B and the immediately 
adjacent CDKN2A genes, we attempted to amplify genomic 
fragments of these genes from multiple Ph+ and Ph− leuke-
mia cell lines. Consistent with previous findings, however 
(18, 19), we found that one or even both genes were already 
deleted in Ph+ (BV173, K562, Nalm1, SUP-B15) and Ph− 
(REH, RS4;11) cell lines, which precluded a comprehensive 
sequence analysis (not depicted). CDKN2A (INK4A, P16) 
and CDKN2B (INK4B, P15) belong to a group of genes that 
encode the INK4 family of tumor suppressors. Interestingly, 
a recent study demonstrated that deletion of another mem-
ber of these gene families, CDKN2D (INK4D, P19/ARF), 
was suffi   cient to render otherwise normal B cells highly 
  susceptible to aberrant chromosomal rearrangements during 
Figure 3.  BCR-ABL1–mediated up-regulation of AID involves re-
pression of ID2, a negative regulator of AID. Two Ph+ ALL cell lines 
(BV173 and SUP-B15) were incubated in the presence or absence of 10 
μmol/l STI571 for 16 h and subjected to microarray analysis using the 
Affymetrix U133A 2.0 platform as described in Materials and methods (A). 
mRNA levels of ID2 were compared with those of AID and its positive reg-
ulators E2A and PAX5. As controls, known STI571-inducible genes (IGKC, 
RAG1, RAG2, and BACH2) are shown. (B) The two Ph+ ALL cell lines were 
cultured for 48 h in the presence or absence of STI571, and protein levels 
of ID2 (top) and AID (bottom) were measured by fl  ow cytometry. (C) To test 
the functional relevance of BCR-ABL1–mediated down-regulation of ID2 
in Ph+ ALL cells, the effect of ID2 overexpression on AID mRNA levels was 
measured in Ph+ ALL cells. Therefore, the two Ph+ ALL cell lines were sta-
bly transduced with a vector encoding only GFP (left) or both GFP and ID2 
(right). Overexpression of ID2 was monitored together with mRNA levels of 
AID. GAPDH mRNA levels were used for normalization of cDNA amounts.JEM VOL. 204, May 14, 2007  1163
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AID-mediated CSR (7). Therefore, the loss of one or more 
of these INK4 tumor suppressors in the context of aberrant 
AID expression in Ph+ ALL may further enhance genetic in-
stability in these leukemia cells.
DISCUSSION
In summary, these fi  ndings identify AID as a mutator within 
but also outside the Ig gene loci in Ph+ ALL cells. Aberrant 
expression of AID leading to SHM of Ig and non-Ig genes is 
Figure 4.  Tracing the clonal evolution of Ph+ ALL cells by VH 
  region gene mutations. Genealogic trees of ongoing SHM of VH gene 
segments amplifi  ed from the Ph+ ALL cell lines NALM1 and BV173 are 
Figure 5.  AID induces DNA-SSB in Ig and non-Ig genes. To estab-
lish a causative link between AID function and the occurrence of DNA-
SSB, AID mRNA expression was silenced in three Ph+ ALL cell lines by RNA 
interference using fl  uorochrome-labeled siRNAs against AID or nontar-
geting siRNA duplexes as a control. Fluorochrome-labeled cells were 
sorted and analyzed for silencing effi  ciency and specifi  city by RT-PCR (A), 
and for DNA-SSB within rearranged VH gene segments and the CDKN2B 
gene by LM-PCR (B). For BV173, Nalm1, and SD1 cells, DNA-SSB inter-
mediates in rearranged VH3-21, VH3-9, and VH3-30 gene segments were 
amplifi  ed, respectively. As a loading control for genomic DNA, VH gene 
rearrangements and a genomic fragment of the CDKN2B gene were 
 amplifi  ed (B). The CDKN2A gene at chromosome 9p21 immediately adjacent 
to CDKN2B was partly or entirely deleted in BV173 and Nalm1 cells, 
precluding LM-PCR analysis of this locus in these cell lines (not depicted).
shown. Numbers indicate the mutated codons within the rearranged V 
region. Each circle represents one VH sequence amplifi  ed from a leukemia 
subclone, and a and b denote distinct mutations within the same codon.1164  ABERRANT SOMATIC HYPERMUTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA | Feldhahn et al.
driven by oncogenic BCR-ABL1 kinase activity and likely 
contributes to the particularly unfavorable prognosis of Ph+ 
leukemia (9). Ph+ leukemias typically carry secondary ge-
netic aberrations (Table S2) and develop resistance to che-
motherapy and inhibition of BCR-ABL1 kinase activity 
within a short period of time (9). Further studies that address 
a specifi  c role of AID in the acquisition of mutations leading 
to drug resistance in Ph+ ALL are currently under way. Of 
note, a small fraction of cases of Ph− pre–B ALL carry mu-
tated VH region genes (and presumably express AID) in the 
absence of BCR-ABL1. This indicates that other aberrations 
besides the Ph may likewise induce aberrant SHM in ALL 
cells. Given that BCR-ABL1–induced up-regulation of AID 
involves repression of ID2 and indirect activation of E2A, 
one would envision that other factors that influence the 
balance between ID2 and E2A may have a similar effect in 
Ph− leukemia cells.
MATERIALS AND METHODS
Patient samples and cell lines. Normal pro–B cells (CD19+ CD34+ μ 
chain−) and pre–B cells (CD19+ VpreB+ μ chain+) were sorted from human 
bone marrow (from four healthy donors; Cambrex) by fl  ow cytometry using 
antibodies from BD Biosciences and a FACSVantage SE cell sorter (BD Bio-
sciences). B1 cells (CD19+ CD5+), naive B cells (CD19+ CD27− IgD+), 
and memory B cells (CD19+ CD27+ IgD−) as well as plasma cells (CD19+ 
CD20− CD138+) were sorted from the peripheral blood of 12 healthy 
  donors (buff  y coats were obtained from the Institute for Blood Transfusion, 
Heinrich-Heine-Universität Düsseldorf) by fl  ow cytometry using the same 
FACS sorter. Human germinal center B cells were isolated from tonsillar re-
sectates provided by T. Hoff  mann (Heinrich-Heine-Universität Düsseldorf). 
To this end, tonsillar B cells were preenriched by MACS using immuno-
magnetic beads against CD19 (Miltenyi Biotec). Thereafter, CD20+ CD38+ 
germinal center B cells were isolated by fl  ow cytometry as described above 
using antibodies from BD Biosciences.
In total, 108 cases of ALL were analyzed for AID expression. 28 cases of 
Ph+ leukemia, including seven cell lines (BV173, CMLT1, K562, NALM1, 
SD1, SUP-B15, and TOM1; DSMZ,) and 80 cases of Ph− ALL, including 
eight cell lines (BEL1, HBP-NULL, KASUMI2, MHH-CALL3, NALM6, 
REH, RS4;11, and 697; DSMZ) were analyzed by RT-PCR (see below). 
Ph+ leukemia also included fi  ve cases of LBC CML (cases 21–25 in Table S2). 
In these cases, CD19+ CD34+ B lymphoid leukemia cells were sorted by 
fl  ow cytometry from leukemic bone marrow samples using antibodies from 
BD Biosciences.
VH gene rearrangements were amplifi  ed and sequenced from 106 cases 
of ALL, including 46 Ph+ and 60 Ph− cases. For 28 cases (18 Ph+, 10 Ph−), 
information on both AID expression and VH region gene sequence was 
available. Cytogenetic data on the patient samples and cell lines studied are 
given in Tables S1 and S2. Patient samples were provided from the Depart-
ment of Hematology and Oncology, Universität Frankfurt (W.-K. Hofmann) 
and the Department of Medical Biosciences, Pathology, Umea University, 
Umea, Sweden (A. Li) in compliance with Institutional Review Board 
regulations. Murine Abelson-MuLV–transformed pre–B cells (300–19) 
were provided by M. Reth (Max-Planck-Institute for Immunobiology, 
Freiburg, Germany). Human Ph+ ALL cells and v-abl–transformed mouse 
pre–B cells were cultured in the presence or absence of 10 μmol/l STI571 
(human ALL) or 1 μmol/l STI571 (murine pre–B cells), respectively. 
STI571 was provided by Novartis. Germinal center–derived B cell lines 
(MHH-PREB1, MN60, Karpas-422, MC116, JEKO-1, and SJO) were 
  obtained from DSMZ.
Induced expression of BCR-ABL1 and ID2. A murine IL-3–dependent 
pro–B cell line, TONB210, which carries an inducible BCR-ABL1 trans-
gene under the control of a doxycycline-dependent promoter (provided by 
G.Q. Daley, Harvard Medical School, Boston, MA), and Ph− ALL cells 
transiently transfected with pMIG-GFP or pMIG-GFP/BCR-ABL1 vectors 
were studied in cell culture experiments as described previously (20). pMIG-
GFP or pMIG-GFP/BCR-ABL1 vectors encode either GFP only or 
GFP and BCRABL1 and were transfected by electroporation (250 V and 
950 μF). For both transfections, GFP+ and GFP− cells were sorted after 24 h 
and subjected to further analysis. BV173 and SUP-B15 cells were transduced 
with the lentiviral vector pCL1 (provided by H. Hanenberg, Heinrich-
  Heine-Universität Düsseldorf, Germany) encoding GFP or GFP and ID2 as 
described previously (21). The coding sequence of the ID2 cDNA (provided 
by E. Hara, Science University of Tokyo, Noda, Japan) was excised with 
BamHI and XhoI and subcloned into pIRESEGFP via BglII and XhoI. The 
expression cassette containing ID2-IRES-EGFP was digested with NheI and 
BsrGI and cloned into the lentiviral vector pCL1. 10 d after lentiviral trans-
duction, GFP+ cells were sorted by fl  ow cytometry and further analyzed or 
kept under cell culture conditions.
Sequence analysis of VH and CH region genes and semiquantitative 
RT-PCR. To characterize the confi  guration of VH and CH region genes, 
two primer sets were used to amplify the V region alone (using VH- and 
JH-specifi  c primers) or the V region together with the constant region (using 
VH- and CH-specifi  c primers) of Ig heavy chain transcripts as described pre-
viously (22) in two rounds of PCR using the primers listed in Table S4, which 
is available at http://www.jem.org/cgi/content/full/jem.20062662/DC1. 
PCR products were then cloned and sequenced.
Mutation analysis of BCL6 and MYC genes. For mutation analysis of 
BCL6 and MYC genes, genomic fragments were amplifi  ed and sequenced as 
described previously (3) using PFU DNA polymerase. For each PCR prod-
uct, both DNA strands were sequenced and mutations were only counted if 
they were found both in the forward and reverse sequence. PCR primers 
used for amplifi  cation of BCL6 and MYC fragments are listed in Table S4.
Mutation analysis of TCRB and TCRG V region genes. TCRB and 
TCRG gene rearrangements were amplifi  ed from multiple leukemia sam-
ples, including Ph+ ALL cell lines, primary leukemia cells from Ph+ LBC 
CML (CD19+ CD34+ B lymphoid cells were sorted from leukemic bone 
marrow samples), and Ph− ALL cell lines. As controls, TCRB and TCRG 
gene rearrangements were amplifi  ed from normal CD3+ T cells (purifi  ed by 
CD3+ MACS from peripheral blood) using the primers listed in Table S4.
Aff  ymetrix GeneChip analysis and semiquantitative RT-PCR. Total 
RNA from cells used for microarray or RT-PCR analysis was isolated by 
RNeasy (QIAGEN) purifi  cation. For microarray analysis, two human Ph+ 
ALL cell lines (BV173, SUP-B15) were cultured for 16 h in the presence or 
absence of 10 μmol/l STI571 (Novartis). Double-strand cDNA was gener-
ated from 5 μg of total RNA using a poly(dT) oligonucleotide that contains 
a T7 RNA polymerase initiation site and the SuperScript III Reverse Tran-
scriptase (Invitrogen). Biotinylated cRNA was generated and fragmented 
according to the Aff  ymetrix protocol and hybridized to U133A 2.0 micro-
arrays (Aff  ymetrix). After scanning (scanner from Aff  ymetrix), the expression 
values for the genes were determined using Aff  ymetrix GeneChip software. 
For semiquantitative RT-PCR analysis of human AID, ID2, GAPDH, and 
BCR-ABL1 and for RT-PCR analysis of murine Aid, Oct2, Obf1, and Hprt 
transcripts, PCR primers are listed in Table S4.
Western blotting and fl  ow  cytometry. For the detection of AID by 
Western blot, an antibody against human AID (L7E7; Cell Signaling Tech-
nology) was used together with the WesternBreeze immunodetection sys-
tem (Invitrogen). Detection of EIF4e was used as a loading control (Santa 
Cruz Biotechnology, Inc.). For analysis of AID and ID2 expression by fl  ow 
cytometry, antibodies against ID2 (rabbit anti–human ID2 IgG; C-20; Santa 
Cruz Biotechnology, Inc.) and AID (mouse anti–human AID IgG1; L7E7; 
Cell Signaling Technology) were used together with secondary antibodies JEM VOL. 204, May 14, 2007  1165
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(goat anti–rabbit IgG Cy2 and goat anti–mouse IgG Cy3; Jackson Immuno-
Research Laboratories). Before staining, cells were fi  xed with 0.4% para-
formaldehyde and incubated for 10 min in 90% methanol on ice.
Silencing of AID mRNA expression by RNA interference. For 
  silencing of AID mRNA expression, one previously validated siRNA (23) 
and a nontargeting siRNA duplex were used. All siRNA duplexes (for se-
quences see Table S4) were labeled with fl  uorescein using an siRNA labeling 
kit (Ambion) according to the manufacturer’s protocol. Fluorochrome-la-
beled siRNA duplexes were transfected into Ph+ ALL cell lines (BV173, 
Nalm1, SD1) by nucleofection according to the manufacturer’s protocol 
(Amaxa). Transfection was repeated after 48 h and transfected fl  uorescein+ 
cells were sorted by FACS after 72 h as described previously (24). RNA 
interference–mediated knockdown of AID mRNA expression was verifi  ed 
by RT-PCR.
Ligation-mediated PCR (LM-PCR) for detection of DNA-SSB. 
  Genomic DNA from 2.5 × 106 cells containing a nick on the lower strand was 
denatured for 10 min at 95°C. Thereafter, a gene-specifi  c primer (Table S4) 
was hybridized and extended to the position of the nick as described previ-
ously (fi  rst strand extension; reference 25), leaving a blunt end using Vent 
DNA polymerase (New England Biolabs, Inc.). Next, a double-stranded 
linker was ligated to the newly created blunt end using T4 DNA ligase 
(Invitrogen) at 14°C overnight. The linker was constructed by annealing of 
the oligonucleotides 5′- T T  T  C  T  G  C  T  C  G  A  A  T  T  C  A  A  G  C  T  T  C  T  A  A  C  G  A  T-
G  T  A  C  G  G  G  G  A  C  A  T  G   3′ and 3′ amino (C7)- G  A  C  G  A  G  C  T  T  A  A  G  T  T  C  -
G  A  A  G  A  T  T  G  C  T  A  C  A  T  G  C  C  C  C  T  -5′, and protruding 3′ overhangs were 
removed by 3′®5′ exonuclease activity of the Klenow fragment of 
  Escherichia coli DNA polymerase I (Invitrogen). LM-PCR (26) was performed 
with modifi  cations as described previously (27). In two semi-nested rounds 
of amplifi  cation at an annealing temperature of 59°C, linker-ligated interme-
diates of DNA-SSB within various genes were amplifi  ed using gene-specifi  c 
primers together with two linker-specifi  c primers (Table S4).
Online supplemental material. Fig. S1 shows the morphology mea-
surement of mRNA levels of Aid in normal mouse splenocytes that were 
stimulated with IL-4 and LPS and treated with or without STI571. Fig. S2 
shows mRNA levels in human B cell lymphoma cells that constitutively 
express AID after treatment with or without STI571. Tables S1–S4 and 
Figs. S1 and S2 are available at http://www.jem.org/cgi/content/full/jem
.20062662/DC1.
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